Lataa...
Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with (177)Lu-labeled PSMA ligands has achieved remarkable results in advanced disease stages of metastatic castration-resistant prostate cancer (mCRPC). However, not all patients benefit from this therapy. Diffe...
Tallennettuna:
| Julkaisussa: | Eur J Nucl Med Mol Imaging |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8113196/ https://ncbi.nlm.nih.gov/pubmed/33336265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05160-8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|